A mineralocorticoid receptor (MR) blocker lowers the expression of monocyte chemoattractant protein 1 (MCP-1) upstream transcription factor NF-kB (nuclear factor-kappa B), renal macrophage infiltration, albuminuria, glomerulosclerosis, and MCP-1 in experimental models (60). Here, CCL2 is linked to glomerulosclerosis.